Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
News|Articles|November 15, 2018
- Pharmaceutical Technology-11-15-2018
- Volume 2018 eBook
- Issue 2
Complex Protein Studies Demand Dynamic Techniques
Author(s)Rita C. Peters
By adapting techniques from other sciences-and exploring better tools for biologics drug development-researchers are addressing challenges of protein characterization.
Advertisement
Proteins must be characterized at many phases of biopharmaceutical research, development, and manufacturing, each with differing demands and requirements. Instrument capabilities-and limitations-influence the speed and success of development efforts. Researchers from biopharma, contract service organizations, and academia face challenges of selecting and optimizing appropriate techniques for protein characterization needs.
Experts interviewed by Pharmaceutical Technology shared similar concerns about the need to conduct complex protein characterization studies under the pressures of tight timelines and urgency to get new drug products to clinic and approval.
Article Details
Pharmaceutical Technology
eBook: Bio/Pharma Laboratory Best Practices 2018
Vol. 42
November 2018
Pages: 42–46
Citation
When referring to this article, please cite it as R. Peters, "Complex Protein Studies Demand Dynamic Techniques," Pharmaceutical Technology Bio/Pharma Laboratory Best Practices eBook (November 2018).
Articles in this issue
almost 8 years ago
Precompetitive Research Spurs Innovation in Pharmaceutical Analysisalmost 8 years ago
Cobots in the Pharma Labalmost 8 years ago
Analytical Best Practices for Raw Materials Testingalmost 8 years ago
Barriers and Solutions to Effective External Collaboration in Biopharmaalmost 8 years ago
Best Practices in Analytical Method Development and Testingalmost 8 years ago
Mixed Reality Gains a Foothold in the LabAdvertisement
Related to this article
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AI Formulation: Regulators Want Data
2
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
3
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
4
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
5